Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.
Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML
Recent Articles
Leading Cancer Researcher Failed to Disclose Industry Funding
An investigation by The New York Times and ProPublica has found that José Baselga, MD, PhD, chief medical officer at Memorial Sloan Kettering Cancer...
AACR Releases Cancer Progress Report
Bipartisan commitment to investing in biomedical science has led to innovations in cancer research, according to the American Association for Cancer Research’s (AACR’s) recently...
Senate Reviewing Legislation Addressing Opioid Epidemic
The U.S. Senate has reached an agreement on a comprehensive bill addressing the opioid epidemic, following the lifting of a legislative hold. The bipartisan...
Major Hospitals Launch Generic Drug Company
Responding to ongoing drug shortages and high prices, several major hospital groups in the U.S. have announced a partnership to manufacture generic drugs.
The new...
Theranos Shutting Down Amid Fraud Allegations
In a letter to investors, the CEO of Theranos announced that the blood-testing company is preparing to shut down. Theranos has faced a U.S....
Current Issue
September 2018, Volume 4, Issue 11
View issue flipbook
September 2018
Volume 4, Issue 11This issue features a look at research misconduct, a debate about whether chronic lymphocytic leukemia is curable, and...
